
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Can it be true, as study suggests, that time allowance for patientoffice visits has lengthened over past decade? Dermatologists respond withtheir experiences